Cargando…

Efficacy and safety of cyclooxygenase 2 inhibitors for desmoid tumor management: a systematic review

The efficacy and safety of cyclooxygenase 2 (COX2) inhibitors for the treatment of desmoid-type fibromatosis (DF) are unclear. Therefore, we systematically reviewed related literature to assess the efficacy and safety of COX2 inhibitors for DF treatment. We searched pertinent literature between Janu...

Descripción completa

Detalles Bibliográficos
Autores principales: Emori, Makoto, Matsumoto, Yoshihiro, Murahashi, Yasutaka, Yoshida, Masahiro, Nishida, Yoshihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nagoya University 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648529/
https://www.ncbi.nlm.nih.gov/pubmed/34916712
http://dx.doi.org/10.18999/nagjms.83.4.673
_version_ 1784610825503244288
author Emori, Makoto
Matsumoto, Yoshihiro
Murahashi, Yasutaka
Yoshida, Masahiro
Nishida, Yoshihiro
author_facet Emori, Makoto
Matsumoto, Yoshihiro
Murahashi, Yasutaka
Yoshida, Masahiro
Nishida, Yoshihiro
author_sort Emori, Makoto
collection PubMed
description The efficacy and safety of cyclooxygenase 2 (COX2) inhibitors for the treatment of desmoid-type fibromatosis (DF) are unclear. Therefore, we systematically reviewed related literature to assess the efficacy and safety of COX2 inhibitors for DF treatment. We searched pertinent literature between January 1999 and August 2017 to identify relevant studies using the keywords “Fibromatosis, aggressive” and “Cyclooxygenase inhibitors.” Thereafter, we screened and determined the quality of the studies using the Grading of Recommendations Assessment, Development, and Evaluation system and extracted the article data. The critical outcomes selected were the efficacy and adverse effects of COX2 inhibitors. Efficacy was evaluated in terms of clinical benefit when patients showed complete response, partial response, and stable disease. Thirty-one articles were identified from the database search, and one was identified through the reviewers’ manual search. Finally, we retrieved six studies, including three case reports, comprising 89 patients after the first and second screenings. Fifty-three patients were excluded because three studies were reported from the same institution; hence, in total, 36 patients were included. Clinical benefit was noted in 64% of the patients. Three adverse effects were identified from the records of the six extracted studies. The strategy of watchful waiting using COX2 inhibitors with few side effects is weakly recommended for DF, especially DF patients with pain.
format Online
Article
Text
id pubmed-8648529
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nagoya University
record_format MEDLINE/PubMed
spelling pubmed-86485292021-12-15 Efficacy and safety of cyclooxygenase 2 inhibitors for desmoid tumor management: a systematic review Emori, Makoto Matsumoto, Yoshihiro Murahashi, Yasutaka Yoshida, Masahiro Nishida, Yoshihiro Nagoya J Med Sci Systematic Review Article The efficacy and safety of cyclooxygenase 2 (COX2) inhibitors for the treatment of desmoid-type fibromatosis (DF) are unclear. Therefore, we systematically reviewed related literature to assess the efficacy and safety of COX2 inhibitors for DF treatment. We searched pertinent literature between January 1999 and August 2017 to identify relevant studies using the keywords “Fibromatosis, aggressive” and “Cyclooxygenase inhibitors.” Thereafter, we screened and determined the quality of the studies using the Grading of Recommendations Assessment, Development, and Evaluation system and extracted the article data. The critical outcomes selected were the efficacy and adverse effects of COX2 inhibitors. Efficacy was evaluated in terms of clinical benefit when patients showed complete response, partial response, and stable disease. Thirty-one articles were identified from the database search, and one was identified through the reviewers’ manual search. Finally, we retrieved six studies, including three case reports, comprising 89 patients after the first and second screenings. Fifty-three patients were excluded because three studies were reported from the same institution; hence, in total, 36 patients were included. Clinical benefit was noted in 64% of the patients. Three adverse effects were identified from the records of the six extracted studies. The strategy of watchful waiting using COX2 inhibitors with few side effects is weakly recommended for DF, especially DF patients with pain. Nagoya University 2021-11 /pmc/articles/PMC8648529/ /pubmed/34916712 http://dx.doi.org/10.18999/nagjms.83.4.673 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ).
spellingShingle Systematic Review Article
Emori, Makoto
Matsumoto, Yoshihiro
Murahashi, Yasutaka
Yoshida, Masahiro
Nishida, Yoshihiro
Efficacy and safety of cyclooxygenase 2 inhibitors for desmoid tumor management: a systematic review
title Efficacy and safety of cyclooxygenase 2 inhibitors for desmoid tumor management: a systematic review
title_full Efficacy and safety of cyclooxygenase 2 inhibitors for desmoid tumor management: a systematic review
title_fullStr Efficacy and safety of cyclooxygenase 2 inhibitors for desmoid tumor management: a systematic review
title_full_unstemmed Efficacy and safety of cyclooxygenase 2 inhibitors for desmoid tumor management: a systematic review
title_short Efficacy and safety of cyclooxygenase 2 inhibitors for desmoid tumor management: a systematic review
title_sort efficacy and safety of cyclooxygenase 2 inhibitors for desmoid tumor management: a systematic review
topic Systematic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648529/
https://www.ncbi.nlm.nih.gov/pubmed/34916712
http://dx.doi.org/10.18999/nagjms.83.4.673
work_keys_str_mv AT emorimakoto efficacyandsafetyofcyclooxygenase2inhibitorsfordesmoidtumormanagementasystematicreview
AT matsumotoyoshihiro efficacyandsafetyofcyclooxygenase2inhibitorsfordesmoidtumormanagementasystematicreview
AT murahashiyasutaka efficacyandsafetyofcyclooxygenase2inhibitorsfordesmoidtumormanagementasystematicreview
AT yoshidamasahiro efficacyandsafetyofcyclooxygenase2inhibitorsfordesmoidtumormanagementasystematicreview
AT nishidayoshihiro efficacyandsafetyofcyclooxygenase2inhibitorsfordesmoidtumormanagementasystematicreview